Results for “”

Entry Author Date Location
Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More 02/28/20 National
Passage Bio’s IPO Raises $216M to Fund Gene Therapy Studies 02/28/20 National
Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK 02/27/20 New York
Gilead, Moderna Candidates Ramp Up Coronavirus Drug, Vaccine Testing 02/27/20 National
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod 02/26/20 Detroit Ann Arbor
Takeda Bases PvP Biologics Buyout on Promising Early Celiac Drug Data 02/26/20 San Diego
With Foamix Merger Weeks Away, Menlo Itching Drug Fails a Phase 2 Test 02/26/20 San Francisco
Bicycle Therapeutics Lands $30M From Genentech in New Cancer R&D Pact 02/25/20 Boston
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System 02/25/20 Europe
Esperion’s FDA-Approved Cholesterol Drug Priced Even Lower Than Expected 02/24/20 Detroit Ann Arbor
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data 02/24/20 San Francisco
Invetx Fetches $15M to Develop Biologic Drugs for Man’s Best Friend 02/24/20 Boston
Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug 02/23/20 National
Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More 02/21/20 National
SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal 02/20/20 Seattle
Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug 02/20/20 San Francisco
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device 02/19/20 Boston
Teva Drug Fails to Beat Placebo in Pediatric Tourette Patient Trials 02/19/20 National
Xcelerating Life Sciences Boston Will Explore Biopharma’s Future in Digital Health 02/19/20 Boston
ResTORbio Pins “Strategic Alternatives” Pitch to Parkinson’s Promise 02/19/20 Boston
Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test 02/18/20 San Francisco
Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic 02/18/20 Boston
New Meds Set to Reshape US CNS and Oncology Markets 02/18/20 National
Agile Therapeutics Wins FDA Nod for Twirla Contraceptive Patch 02/14/20 New York
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More 02/14/20 National
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks 02/13/20 National
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer 02/12/20 San Francisco
Ligand’s Icagen Deal Brings Neuro, CF Assets Plus Partnering Potential 02/12/20 San Diego
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019 02/12/20 National
Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. 02/11/20 National
Page 1 of 1960 next page »